J&J pays $120M to settle charges of deceptive hip-implant marketing

Johnson & Johnson will pay $120 million to resolve allegations that it used deceptive marketing techniques to sell its metal-on-metal hip implants, according to Bloomberg.

The claims, brought by 46 attorneys general, alleged J&J and its DePuy unit wrongly advertised that more than 90 percent of the devices lasted at least five years. European health regulators instead found the survival rates to be around 5 percent.

"Companies should never be allowed to freely mislead the public, especially when there are health concerns involved," New York Attorney General Letitia James told Bloomberg. "This settlement serves as an important message that deceptive and false medical practices will never be tolerated."

A spokesperson for the DePuy subsidiary said the company is not admitting liability or misconduct.

The settlement resolves litigation with 46 states.

More articles on legal and regulatory issues:
Walgreens pays $269M to settle billing fraud lawsuits
14 latest healthcare industry lawsuits, settlements
UnitedHealth sues dozens of drug companies for price-fixing

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months